BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.

In our EuroBiotech roundup this week, Galapagos delays cystic fibrosis program, Zealand heads to phase 3 and Pluristem loses out on $30 million. 

In this week's EuroBiotech Report, J&J spins out Idorsia, Bavarian Nordic delays data, Woodford backs dementia fund and more. 

Biotech stocks are enjoying their most buoyant patch in months, after reports President Trump's crackdown on pricing may not be as tough as feared.

ElexoPharm has licensed inhibitors of the aldosterone synthase enzyme to Angion Biomedica.

Eli Lilly has completed the expansion of its biotech facility in San Diego, California. The $90 million expansion has added 180,000 square feet to the 125,000-…

Repare Therapeutics has emerged from stealth mode with an impressive $68 million.

Vineti is launching its cloud-based system to streamline company processes and accelerate patient access to cell and gene therapies.

Clinigen has signed exclusive agreements with Mitsubishi Tanabe, Shionogi and Romark to cooperate on expanded access to their medicines.

Sarepta Therapeutics has penned its second DMD gene therapy pact this year.